Evidence map›Paper›PMID 25924916›Full record

ArticleBMC genomics2015

Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression.

Denis Grandgirard, Leonardo Furi, Maria Laura Ciusa, Lucilla Baldassarri, Daniel R Knight, Ian Morrissey, Carlo R Largiadèr, Stephen L Leib, Marco R Oggioni

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. The mobilome landscape of biocide-resistance in Brazilian ESKAPE isolates.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Construction of aHeliyon · 2020
    Article
  10. Susceptibility of livestock-associated methicillin-resistantAntimicrobial resistance and infection control · 2019
    Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 5 countries.

Denis GrandgirardNeuroinfection Laboratory, Institute for Infectious Diseases, University of Bern, Bern, Switzerland. denis.grandgirard@ifik.unibe.ch.
Leonardo FuriLA.M.M.B., Dip. Biotecnologie Mediche, Università di Siena, Siena, Italy. leofuri@libero.it.
Maria Laura CiusaLA.M.M.B., Dip. Biotecnologie Mediche, Università di Siena, Siena, Italy. laciusa@gmail.com.
Lucilla BaldassarriIstituto Superiore di Sanità, Roma, Italy. lucilla.baldassarri@iss.it.
Daniel R KnightQuotient Bioresearch, Fordham, UK. daniel.knight@uwa.edu.au.
Ian MorrisseyQuotient Bioresearch, Fordham, UK. i.morrissey@ntlworld.com.
Carlo R LargiadèrInstitute of Clinical Chemistry, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. carlo.largiader@insel.ch.
Stephen L LeibNeuroinfection Laboratory, Institute for Infectious Diseases, University of Bern, Bern, Switzerland. Stephen.leib@ifik.unibe.ch.
Marco R OggioniLA.M.M.B., Dip. Biotecnologie Mediche, Università di Siena, Siena, Italy. mro5@leicester.ac.uk.
University of Siena · ITUniversity of Bern · CHAssociation for Symbolic Logic · USIstituto Superiore di Sanità · ITThe University of Western Australia · AUUniversity Hospital of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe enoyl-acyl carrier protein (ACP) reductase enzyme (FabI) is the target for a series of antimicrobial agents including novel compounds in clinical trial and the biocide triclosan. Mutations in fabI and heterodiploidy for fabI have been shown to confer resistance in S. aureus strains in a previous study. Here we further determined the fabI upstream sequence of a selection of these strains and the gene expression levels in strains with promoter region mutations.

resultsMutations in the fabI promoter were found in 18% of triclosan resistant clinical isolates, regardless the previously identified molecular mechanism conferring resistance. Although not significant, a higher rate of promoter mutations were found in strains without previously described mechanisms of resistance. Some of the mutations identified in the clinical isolates were also detected in a series of laboratory mutants. Microarray analysis of selected laboratory mutants with fabI promoter region mutations, grown in the absence of triclosan, revealed increased fabI expression in three out of four tested strains. In two of these strains, only few genes other than fabI were upregulated. Consistently with these data, whole genome sequencing of in vitro selected mutants identified only few mutations except the upstream and coding regions of fabI, with the promoter mutation as the most probable cause of fabI overexpression. Importantly the gene expression profiling of clinical isolates containing similar mutations in the fabI promoter also showed, when compared to unrelated non-mutated isolates, a significant up-regulation of fabI.

conclusionsIn conclusion, we have demonstrated the presence of C34T, T109G, and A101C mutations in the fabI promoter region of strains with fabI up-regulation, both in clinical isolates and/or laboratory mutants. These data provide further observations linking mutations upstream fabI with up-regulated expression of the fabI gene.

Indexed as

Anti-Infective Agents, LocalBacterial ProteinsBase SequenceDown-RegulationDrug Resistance, BacterialEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)GenotypeMolecular Sequence DataMutationPromoter Regions, GeneticStaphylococcus aureusTriclosanUp-RegulationAnti-Infective Agents, LocalBacterial ProteinsEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)Triclosan

Identifiers

PMID25924916
PMCPMC4415318
OpenAlexW2047701008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.